Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

2.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.2K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

14.8K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
14.8K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

83.5K
Overview
83.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

16.0K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
16.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering CAR-Vδ2 T cells to boost persistence and anti-tumor function.

bioRxiv : the preprint server for biology·2026
Same author

Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor.

Nature communications·2026
Same author

CART-007: a license to kill.

Blood·2025
Same author

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.

Blood advances·2025
Same author

Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy.

Stem cells translational medicine·2025
Same author

CD7 CAR-T: a bridge to transplant in AML.

Blood·2025
Same journal

Targeting cholesterol esterification sensitizes liver cancer to CD8<sup>+</sup> T cell attack by impairing metabolic and redox resilience.

Immunity·2026
Same journal

Brain endothelial cells orchestrate a neuroprotective antiviral state in the CNS in response to peripheral viral pattern sensing.

Immunity·2026
Same journal

Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors.

Immunity·2026
Same journal

B cell-derived type I interferon sustains T cell functionality upon strong TCR stimulation during chronic infection.

Immunity·2026
Same journal

Lactate binds and inhibits the innate immune sensor STING to promote tumor immune evasion.

Immunity·2026
Same journal

Antibody binding geometry and affinity control inhibitory hFcγRIIB receptor signaling.

Immunity·2026
See all related articles

Related Experiment Video

Updated: Jan 17, 2026

A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model
08:38

A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model

Published on: March 3, 2023

1.7K

To the nines: IL-9 boosts T cell function.

Elizabeth Wickman1, Maksim Mamonkin1

  • 1Columbia Initiative in Cell Engineering and Therapy, Columbia University Irving Medical Center, New York, NY, USA; Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, USA.

Immunity
|January 14, 2026
PubMed
Summary
This summary is machine-generated.

Interleukin-9 (IL-9) signaling in T cells boosts their persistence and anti-tumor capabilities in solid cancer models, expanding its known roles beyond immunity to parasites and allergies.

More Related Videos

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.9K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

15.2K

Related Experiment Videos

Last Updated: Jan 17, 2026

A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model
08:38

A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model

Published on: March 3, 2023

1.7K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.9K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

15.2K

Area of Science:

  • Immunology
  • Cancer Biology
  • T cell Biology

Background:

  • Interleukin-9 (IL-9) is traditionally recognized for its roles in anti-helminth and allergic immune responses.
  • The specific functions of IL-9 signaling within T cells in the context of cancer immunity are less understood.

Purpose of the Study:

  • To investigate the impact of integrating IL-9 signaling within T cells on their function in solid cancer models.
  • To explore novel therapeutic strategies targeting IL-9 for cancer treatment.

Main Methods:

  • Utilized solid cancer models to assess T cell responses.
  • Investigated the effects of modulating IL-9 signaling pathways in T cells.

Main Results:

  • Demonstrated that IL-9 signaling enhances T cell persistence in solid tumors.
  • Showed that IL-9 signaling improves the anti-tumor function of T cells.
  • Identified a novel role for IL-9 in promoting anti-cancer immunity.

Conclusions:

  • IL-9 signaling in T cells is a critical factor for enhancing anti-tumor immunity in solid cancers.
  • Targeting IL-9 pathways represents a promising avenue for improving cancer immunotherapy.